All In Biotech

Drug Trial Radar · NCT05211986

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

An Open-label Dose Escalation Study to Assess the Safety and Tolerability of IMM01-STEM in Participants With Muscle Atrophy Related to Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Sep 13, 2022

Primary completion

Jul 27, 2026

Study completion Jul 27, 2026

Sponsor

Lead sponsor
Immunis, Inc.Industry
Sponsor type
Industry
First posted
Jan 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis

Conditions

  • Muscle Atrophy

Interventions

  • IMM01-STEMDrug

    IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of IMMUNA(IMM01-STEM) treatment in study participants with muscle atrophy related to KOATime frame: Day 0 to Day 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orthopaedic Specialty Institute

    Irvine, California

  • University of California, Irvine - Alpha Stem Cell Clinic

    Orange, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.